Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

6 clinical studies listed.

Filters:

Chemotherapy Induced Alopecia

Tundra lists 6 Chemotherapy Induced Alopecia clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

NOT YET RECRUITING

NCT07397325

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia

Gender: FEMALE

Ages: 18 Years - 65 Years

Updated: 2026-04-09

Chemotherapy Induced Alopecia
Chemotherapy Side Effects
NOT YET RECRUITING

NCT07402330

Pharmacokinetic Study of DA-020

Pharmacokinetic Study of DA-020

Gender: FEMALE

Ages: 18 Years - 55 Years

Updated: 2026-02-12

Chemotherapy Induced Alopecia
Chemotherapy Side Effects
RECRUITING

NCT07033845

Pharmacokinetic Study of Topical Phenylephrine

Pharmacokinetic Study of Topical Phenylephrine

Gender: FEMALE

Ages: 18 Years - 55 Years

Updated: 2025-10-03

Chemotherapy Induced Alopecia
Chemotherapy Side Effects
ACTIVE NOT RECRUITING

NCT07201389

CARE (Chemotherapy Alopecia REduction)

The goal of this research study is to determine if the DigniCap Scalp Cooling System can help prevent chemotherapy-induced hair loss in Black patients.

Gender: FEMALE

Ages: 21 Years - Any

Updated: 2025-10-01

1 state

Breast Cancer
Breast - Female
Breast Cancer Stage I
+3
NOT YET RECRUITING

NCT06762548

Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia

Clinical Study of DA-007 As a Treatment for Chemotherapy Induced Alopecia

Gender: FEMALE

Ages: 18 Years - 65 Years

Updated: 2025-05-23

Chemotherapy Induced Alopecia
Chemotherapy Side Effects
RECRUITING

NCT06786078

The Lily Device Trial

The goal of this clinical trial is to test if the Lily Device works to reduce chemotherapy induced hair loss in patients. It will also learn about the safety of the Lily Device. The main questions it aims to answer is: * Do patient preserve their hair using the Lily Device after 4 cycles of chemotherapy, when hair preservation is a Grade ≤1 graded by an independent healthcare professional on the Common Terminology Criteria for Adverse Events (CTCAE)? * What is the subject incidence of Grade 1 or above Adverse Device Events (ADE's)?

Gender: All

Ages: 18 Years - Any

Updated: 2025-01-22

3 states

Chemotherapy Induced Alopecia